This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Rigel Pharmaceuticals, Inc.
Drug Names(s): tamatinib fosdium, R406/788, R935788, FosD, R788
Description: R788 is an oral syk kinase inhibitor that can block activation of mast cells and B cells, inhibiting swelling and inflammatory responses. Syk inhibitors can also block inflammatory mediators, including TNF and various interleukins.
R406/788 is an oral solid dosage formulation of R406.
Deal Structure: R788 was originally developed by Rigel Pharmaceuticals.
In February 2010, AstraZeneca and Rigel Pharmaceuticals announced an exclusive worldwide license agreement for the global development and commercialisation of fostamatinib disodium (R788) for rheumatoid arthritis (RA) and additional indications. AstraZeneca will make an upfront payment to Rigel of $100 million with up to an additional $345 million payable if specified development, regulatory and first commercial sale milestones are achieved. Rigel will also be eligible to receive up to an additional $800 million of specified sales-related milestone payments if the product achieves considerable levels of commercial success, as well as significant stepped double-digit royalties on net sales worldwide. AstraZeneca is responsible for all development, regulatory filings, manufacturing and global commercialisation activities in all licensed indications under the contract.
BioMedTracker has estimated a rough 80/20 revenue...See full deal structure in Biomedtracker
Additional information available to subscribers only: